TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$150 Million

Geron Corporation

Underwritten Offering

Lead Left Bookrunner, March 2024

Geron Corporation

Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying drivers of disease.